CfDNA in Hereditary And High-risk Malignancies 2 (NCT06726642)
CfDNA in Hereditary And High-risk Malignancies (CHARM) 2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will compare cancer detection rates between those receiving the new blood test and those receiving standard care, assess if the test leads to earlier cancer diagnosis, and evaluate its impact on patient outcomes. The study will also use questionnaires and interviews to understand how patients feel about the blood test, its incorporation into routine medical care, and perceptions of the medical value of test results. This research could lead to more effective and less invasive cancer screening for high-risk individuals.
Who can join: Review the eligibility criteria below.
Location: BC Cancer Agency — Vancouver, British Columbia
Age range: Not specified to 90 Years
🧪 Interventions in This Study
- Cell-free DNA analysis (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- BC Cancer Agency — Vancouver, British Columbia
- Eastern Health — St. John's, Newfoundland and Labrador
- IWK Health Centre — Halifax, Nova Scotia
- The Hospital for Sick Children — Toronto, Ontario
- Sinai Health System — Toronto, Ontario
- University Health Network — Toronto, Ontario
- Women's College Hospital — Toronto, Ontario
- Jewish General Hospital — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (416) 409-1387
Email: charm@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Cancer Syndrome
- Cell-free DNA in Hereditary And High-Risk Malignancies 1 — Vancouver, British Columbia
- Integrative Sequencing In Germline and Hereditary Tumours — Toronto, Ontario
- Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) — Chicago, Illinois
- Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening — New York, New York
Explore by condition: All Hereditary Cancer Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.